Enhanced Depth Navigation Through Augmented Reality Depth Mapping in Patients with Low Vision.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 08 2019
Historique:
received: 20 05 2019
accepted: 15 07 2019
entrez: 4 8 2019
pubmed: 4 8 2019
medline: 20 11 2020
Statut: epublish

Résumé

Patients diagnosed with Retinitis Pigmentosa (RP) show, in the advanced stage of the disease, severely restricted peripheral vision causing poor mobility and decline in quality of life. This vision loss causes difficulty identifying obstacles and their relative distances. Thus, RP patients use mobility aids such as canes to navigate, especially in dark environments. A number of high-tech visual aids using virtual reality (VR) and sensory substitution have been developed to support or supplant traditional visual aids. These have not achieved widespread use because they are difficult to use or block off residual vision. This paper presents a unique depth to high-contrast pseudocolor mapping overlay developed and tested on a Microsoft Hololens 1 as a low vision aid for RP patients. A single-masked and randomized trial of the AR pseudocolor low vision aid to evaluate real world mobility and near obstacle avoidance was conducted consisting of 10 RP subjects. An FDA-validated functional obstacle course and a custom-made grasping setup were used. The use of the AR visual aid reduced collisions by 50% in mobility testing (p = 0.02), and by 70% in grasp testing (p = 0.03). This paper introduces a new technique, the pseudocolor wireframe, and reports the first significant statistics showing improvements for the population of RP patients with mobility and grasp.

Identifiants

pubmed: 31375713
doi: 10.1038/s41598-019-47397-w
pii: 10.1038/s41598-019-47397-w
pmc: PMC6677879
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11230

Références

Acta Ophthalmol Scand Suppl. 2002;(233):1-34
pubmed: 11921605
PLoS One. 2017 Apr 26;12(4):e0176534
pubmed: 28445540
PLoS One. 2013 Jul 03;8(7):e67695
pubmed: 23844067
Ophthalmic Physiol Opt. 2002 Mar;22(2):79-91
pubmed: 12014491
Elife. 2018 Nov 27;7:
pubmed: 30479270
Optom Vis Sci. 2018 Sep;95(9):727-737
pubmed: 29877901
Arch Ophthalmol. 2007 Feb;125(2):151-8
pubmed: 17296890
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4802-9
pubmed: 26218908
Optom Vis Sci. 1994 Jul;71(7):442-53
pubmed: 7970559
Lancet. 2006 Nov 18;368(9549):1795-809
pubmed: 17113430
Curr Biol. 2007 Feb 20;17(4):366-72
pubmed: 17291762
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):65-71
pubmed: 16384945
Optometry. 2010 Sep;81(9):461-8
pubmed: 20591747
Optom Vis Sci. 1996 Oct;73(10):621-37
pubmed: 8916133
Am J Ophthalmol. 1966 Jul;62(1):27-37
pubmed: 5936523
Sensors (Basel). 2019 Apr 05;19(7):
pubmed: 30959756
Science. 1971 Oct 15;174(4006):314-6
pubmed: 5119106
Clin Exp Ophthalmol. 2018 Apr;46(3):247-259
pubmed: 28697537
Appl Bionics Biomech. 2015;2015:543492
pubmed: 27019586
Optom Vis Sci. 1998 Jul;75(7):525-37
pubmed: 9703042
J Chronic Dis. 1969 Aug;22(3):133-51
pubmed: 4897966
Optom Vis Sci. 2016 Sep;93(9):1127-36
pubmed: 27254810
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2571-9
pubmed: 25788655
J Neural Eng. 2013 Apr;10(2):026017
pubmed: 23449023
Orphanet J Rare Dis. 2006 Oct 11;1:40
pubmed: 17032466
Br J Ophthalmol. 1984 Aug;68(8):561-9
pubmed: 6743626
Clin Exp Optom. 2007 Mar;90(2):115-23
pubmed: 17311573
Eye (Lond). 2017 May;31(5):741-748
pubmed: 28085147
Transl Vis Sci Technol. 2014 Dec 30;3(7):9
pubmed: 25653893
Eye (Lond). 2010 Apr;24(4):535-9
pubmed: 19590526
J Vis Exp. 2014 Feb 11;(84):e51205
pubmed: 24561717
Curr Genomics. 2011 Jun;12(4):236-7
pubmed: 22131868

Auteurs

Anastasios Nikolas Angelopoulos (AN)

University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA. nikolasa@stanford.edu.
Stanford University, Department of Electrical Engineering, Stanford, 94301, USA. nikolasa@stanford.edu.

Hossein Ameri (H)

University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA.
University of Southern California Keck School of Medicine, USC Roski Eye Institute, Los Angeles, 90033, USA.

Debbie Mitra (D)

University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA.
University of Southern California Keck School of Medicine, USC Roski Eye Institute, Los Angeles, 90033, USA.

Mark Humayun (M)

University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA. humayun@med.usc.edu.
University of Southern California Keck School of Medicine, USC Roski Eye Institute, Los Angeles, 90033, USA. humayun@med.usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH